Dr. Yi Lu graduated with a B.S. degree in Biochemistry from Fudan University in Shanghai, China in 1984, and a Ph.D. degree in Biochemistry and Molecular Biology from the University of Nebraska Medical Center, Omaha, NE, USA in 1992. After completing his postdoctoral training at the University of Texas M.D. Anderson Cancer Center in Houston, TX, USA, Dr. Lu joined the faculty of the University of Tennessee Health Science Center (UTHSC), Memphis, TN, USA in 1995 as the Director of Gene Therapy, Department of Urology. He is currently an Associate Professor at the Departments of Pathology, Medicine, Urology and Pharmaceutical Sciences at UTHSC. Dr. Lu has contributed pioneering work in adenoviral vector-based gene therapy for prostate cancer including the comparison study of vector delivery routes to the prostate, development of prostate-specific targeting vectors, and oncolytic virotherapy. His group also cloned and performed functional analysis of a novel apoptosis-inducing gene pHyde. Dr. Lu’s current research interests include tumor angiogenesis and metastasis, viral-based gene therapy for prostate cancer and breast cancer, targeted gene expression, and exploration of novel anti-HIF-1? agents. He has also served as a consultant for several biotech companies, national study sections, and currently holds an active NIH R01 grant. Dr. Lu is on several editorial boards and a co-editor of the book “Pharmaceutical Perspectives of Cancer Therapeutics”. He has more than 50 publications and holds five patents.